Show simple item record

Authordc.contributor.authorVelasco Aguirre, Carolina 
Authordc.contributor.authorMorales, Francisco 
Authordc.contributor.authorGallardo Toledo, Eduardo 
Authordc.contributor.authorGuerrero, Simón 
Authordc.contributor.authorGiralt, Ernest 
Authordc.contributor.authorAraya, Eyleen 
Authordc.contributor.authorKogan Bocian, Marcelo 
Admission datedc.date.accessioned2015-11-05T18:26:04Z
Available datedc.date.available2015-11-05T18:26:04Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationInternational Journal of Nanomedicine 2015:10en_US
Identifierdc.identifier.otherDOI: 10.2147/IJN.S82310
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/134865
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractAn exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood-brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.en_US
Patrocinadordc.description.sponsorshipFONDECYT 11130494 1130425 FONDAP 15130011 UNAB DI569-14/R MECESUP UCH-0811en_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherDove Medical Pressen_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectBlood-brain barrieren_US
Keywordsdc.subjectCentral nervous systemen_US
Keywordsdc.subjectTranscytosisen_US
Keywordsdc.subjectDrug deliveryen_US
Keywordsdc.subjectEPR effecten_US
Keywordsdc.subjectBiodistributionen_US
Títulodc.titlePeptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approachesen_US
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile